Blood thinners for preventing another clot in low-risk APS
Part of Blood & lymphatic, Heart & circulation, Immune system & allergy clinical trials.
This study looks at how well blood thinners prevent blood clots from coming back in people with antiphospholipid syndrome (APS) who are considered low risk. It compares two types of medicines: direct oral anticoagulants (DOACs) and vitamin K antagonists.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older and have antiphospholipid syndrome (APS) with a history of blood clots.
- Your APS must be low risk, meaning you had a clot in a vein before and test positive for one or two specific antibodies (not all three).
- You are already on a blood thinner like a DOAC or warfarin to prevent more clots.
- You have been taking this blood thinner steadily for at least 2 weeks before joining the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two types of blood thinners (DOACs like rivaroxaban/apixaban vs. warfarin) in people with antiphospholipid syndrome who have had a vein clot. The goal is to see which works better to prevent future clots.
This research study looks at people with antiphospholipid syndrome (APS) who have taken or are taking direct oral anticoagulants (DOACs), which are blood thinners. The goal is to collect information about their treatment and health over time.
This study keeps a registry to follow people with antiphospholipid syndrome (APS) who have had arterial blood clots (like stroke). It collects information about the treatment approach your clinician chooses to see how different antithrombotic regimens may perform and be tolerated.
This study compares two types of blood thinners — clopidogrel (an antiplatelet) and warfarin — to prevent another stroke in people with antiphospholipid syndrome (APS). It aims to find which medicine works better for people who have already had a stroke related to APS.
This study keeps an international registry of people with antiphospholipid syndrome (APS) who are taking direct oral blood thinners. It may help doctors better understand how APS patients do over time and improve future care, even if you’re not asked to change treatment.
This study tests a new quick blood-clotting test (point-of-care INR testing) for patients with antiphospholipid syndrome who take blood thinners. The goal is to see if this faster test works as well as standard lab tests for monitoring their treatment.
Hear when a new Antiphospholipid Syndrome (APS) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.